915 / 1266
PAge68
1/25/2016 |
Author
Division
a
Olaf Witt
SIOP LGG 201X
Studiendesign
Aims of the Trial
•
Reduction of neurotoxicity
•
Introduce
combined primary endpoint
:
+ PFS (MRI)
+ neurological function (VABS II)
+ visual function (VA, LogMAR)
•
Biology:
biomarker for prediction of natural course of LGG,
prediction response to chemotherapy/targeted therapy
•
Introduction of
targeted compounds
asap after promising phase
II data